Endotoxin release in cardiac surgery with cardiopulmonary bypass: Pathophysiology and possible therapeutic strategies. An update

European Journal of Cardio-thoracic Surgery

Volumn 39, Issue 4, 2011, Pages 451-458

  Kats, Suzanne ^a   Schönberger, Jacques P A M ^a   Brands, Ruud ^b   Seinen, Willem ^b   van Oeveren, Wim ^c  

^a CATHARINA HOSPITAL   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Cardiopulmonary bypass; Endotoxin release; Inflammatory response syndrome

Indexed keywords

ALKALINE PHOSPHATASE; AMPHOTERICIN B; C REACTIVE PROTEIN; CD14 ANTIGEN; COLISTIN; CORTICOSTEROID; ENDOTOXIN; ENDOTOXIN ANTIBODY; ERITORAN; HUMORAL ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; KETANSERIN; LIPOPOLYSACCHARIDE; LIPOPOLYSACCHARIDE BINDING PROTEIN; METHYLPREDNISOLONE; NEOMYCIN; PENTRAXIN; PICOSULFATE SODIUM; PLACEBO; POLYMYXIN B; TAUROLIDINE; TOBRAMYCIN; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ANTIINFLAMMATORY ACTIVITY; AORTA CLAMPING; AORTA VALVE REPLACEMENT; ATHEROSCLEROSIS; BODY TEMPERATURE; CARDIOPULMONARY BYPASS; CAROTID ARTERY SURGERY; CELLULAR IMMUNITY; CHEMICAL STRUCTURE; CLINICAL TRIAL; CYTOKINE RELEASE; DETOXIFICATION; DEVICE; DISINFECTION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MEGADOSE; ENDOTOXEMIA; ENDOTOXIN RELEASE; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; EXTRACORPOREAL CIRCULATION; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HEART VALVE SURGERY; HOSPITALIZATION; HUMAN; HUMORAL IMMUNITY; HYPOTHERMIA; ISCHEMIA; LIMULUS LYSATE TEST; LOW DRUG DOSE; MITRAL VALVE REPLACEMENT; NONHUMAN; OFF PUMP SURGERY; ON PUMP SURGERY; PATHOPHYSIOLOGY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PULSATILE FLOW; REVIEW; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

ADRENAL CORTEX HORMONES; ALKALINE PHOSPHATASE; ANTI-INFECTIVE AGENTS; ANTIBODIES; CARDIOPULMONARY BYPASS; CYTOKINES; DISACCHARIDES; ENDOTOXINS; HEMOPERFUSION; HUMANS; HYPOTHERMIA, INDUCED; KETANSERIN; SEROTONIN ANTAGONISTS; SUGAR PHOSPHATES; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TAURINE; THIADIAZINES; TOLL-LIKE RECEPTOR 4;

EID: 79952535561     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcts.2010.06.011     Document Type: Review

References (63)

1. Paparella D., Yau T.M., Young E. Cardiopulmonary bypass induced inflammation: pathophysiology and treatment. An update. Eur J Cardiothorac Surg 2002, 21:232-244.
2. Suffredini A.F., Fromm R.E., Parker M.M., Brenner M., Kovacs J.A., Wesley R.A., Parrillo J.E. The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med 1989, 321:280-287.
3. Rietschel E.T., Kirikae T., Schade F.U., Mamat U., Schmidt G., Loppnow H., Ulmer A.J., Zahringer U., Seydel U., Di P.F. Bacterial endotoxin: molecular relationships of structure to activity and function. FASEB J 1994, 8:217-225.
4. Raetz C.R. Biochemistry of endotoxins. Annu Rev Biochem 1990, 59:129-170.
5. Chow J.C., Young D.W., Golenbock D.T., Christ W.J., Gusovsky F. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J Biol Chem 1999, 274:10689-10692.
6. Andersen L.W., Baek L., Degn H., Lehd J., Krasnik M., Rasmussen J.P. Presence of circulating endotoxins during cardiac operations. J Thorac Cardiovasc Surg 1987, 93:115-119.
7. Nilsson L., Kulander L., Nystrom S.O., Eriksson O. Endotoxins in cardiopulmonary bypass. J Thorac Cardiovasc Surg 1990, 100:777-780.
8. Rocke D.A., Gaffin S.L., Wells M.T., Koen Y., Brock-Utine J.G. Endotoxemia associated with cardiopulmonary bypass. J Thorac Cardiovasc Surg 1987, 93:832-837.
9. Ohri S.K., Bjarnason I., Pathi V., Somasundaram S., Bowles C.T., Keogh B.E., Khaghani A., Menzies I., Yacoub M.H., Taylor K.M. Cardiopulmonary bypass impairs small intestinal transport and increases gut permeability. Ann Thorac Surg 1993, 55:1080-1086.
10. Ohri S.K., Becket J., Brannan J., Keogh B.E., Taylor K.M. Effects of cardiopulmonary bypass on gut blood flow, oxygen utilization, and intramucosal pH. Ann Thorac Surg 1994, 57:1193-1199.
11. Riddington D.W., Venkatesh B., Boivin C.M., Bonser R.S., Elliott T.S., Marshall T., Mountford P.J., Bion J.F. Intestinal permeability, gastric intramucosal pH, and systemic endotoxemia in patients undergoing cardiopulmonary bypass. JAMA 1996, 275:1007-1012.
12. Bjarnason I., O'Morain C., Levi A.J., Peters T.J. Absorption of 51chromium-labeled ethylenediaminetetraacetate in inflammatory bowel disease. Gastroenterology 1983, 85:318-322.
13. Oudemans-van Straaten H.M., Hoek F.J., van Deventer S.J. Gastrointestinal permeability in cardiac surgery patients, the interpretation of dual-sugar absorption studies. Intensive Care Med 1997, 23:1101-1102.
14. Oudemans-van Straaten H.M., Jansen P.G., Hoek F.J., van Deventer S.J., Sturk A., Stoutenbeek C.P., Tytgat G.N., Wildevuur C.R., Eysman L. Intestinal permeability, circulating endotoxin, and postoperative systemic responses in cardiac surgery patients. J Cardiothorac Vasc Anesth 1996, 10:187-194.
15. Jansen N.J., van O.W., Gu Y.J., van Vliet M.H., Eijsman L., Wildevuur C.R. Endotoxin release and tumor necrosis factor formation during cardiopulmonary bypass. Ann Thorac Surg 1992, 54:744-747.
16. Fingerle-Rowson G., Auers J., Kreuzer E., Labeta M., Schmidt B., Samtleben W., Ziegler-Heitbrock H.W., Blumenstein M. Down-regulation of surface monocyte lipopolysaccharide-receptor CD14 in patients on cardiopulmonary bypass undergoing aorta-coronary bypass operation. J Thorac Cardiovasc Surg 1998, 115:1172-1178.
17. Spanier T., Tector K., Schwartz G., Chen J., Oz M., Beck J., Mongero L. Endotoxin in pooled pericardial blood contributes to the systemic inflammatory response during cardiac surgery. Perfusion 2000, 15:427-431.
18. Baek L., Tvede M., Mikkelsen T. [Limulus amoebocyte lysate (LAL) test for demonstration of endotoxins]. Ugeskr Laeger 1980, 142:1405-1409.
19. Boelke E., Storck M., Buttenschoen K., Berger D., Hannekum A. Endotoxemia and mediator release during cardiac surgery. Angiology 2000, 51:743-749.
20. Videm V., Svennevig J.L., Fosse E., Mohr B., Aasen A.O. Plasma endotoxin concentrations during cardiac surgery may be related to atherosclerosis. Perfusion 2000, 15:421-426.
21. Lowry S.F. Human endotoxemia: a model for mechanistic insight and therapeutic targeting. Shock 2005, 24(Suppl. 1):94-100.
22. Kudlova M., Kunes P., Kolackova M., Lonsky V., Mandak J., Andrys C., Jankovicova K., Krejsek J. Lipopolysaccharide binding protein and sCD14 are not produced as acute phase proteins in cardiac surgery. Mediators Inflamm 2007, 2007:72356.
23. Grundmann U., Rensing H., Adams H.A., Falk S., Wendler O., Ebinger N., Bauer M. Endotoxin desensitization of human mononuclear cells after cardiopulmonary bypass: role of humoral factors. Anesthesiology 2000, 93:359-369.
24. Fitting C., Dhawan S., Cavaillon J.M. Compartmentalization of tolerance to endotoxin. J Infect Dis 2004, 189:1295-1303.
25. Barclay G.R. Bacterial endotoxins: lipopolysaccharides from genes to therapy. Progress in clinical and biological research 1995, 263-272. John Wiley and Sons, New York. J. Levin, C.R. Alving, R.S. Munford, H. Redl (Eds.).
26. Scott B.B., Barclay G.R. Endotoxin-polymyxin complexes in an improved enzyme-linked immunosorbent assay for IgG antibodies in blood donor sera to gram-negative endotoxin core glycolipids. Vox Sang 1987, 52:272-280.
27. Bennett-Guerrero E., Ayuso L., Hamilton-Davies C., White W.D., Barclay G.R., Smith P.K., King S.A., Muhlbaier L.H., Newman M.F., Mythen M.G. Relationship of preoperative antiendotoxin core antibodies and adverse outcomes following cardiac surgery. JAMA 1997, 277:646-650.
28. Hamilton-Davies C., Barclay G.R., Cardigan R.A., McDonald S.J., Purdy G., Machin S.J., Webb A.R. Relationship between preoperative endotoxin immune status, gut perfusion, and outcome from cardiac valve replacement surgery. Chest 1997, 112:1189-1196.
29. Mathew J.P., Grocott H.P., Phillips-Bute B., Stafford-Smith M., Laskowitz D.T., Rossignol D., Blumenthal J.A., Newman M.F. Lower endotoxin immunity predicts increased cognitive dysfunction in elderly patients after cardiac surgery. Stroke 2003, 34:508-513.
30. Rothenburger M., Soeparwata R., Deng M.C., Berendes E., Schmid C., Tjan T.D., Wilhelm M.J., Erren M., Bocker D., Scheld H.H. The impact of anti-endotoxin core antibodies on endotoxin and cytokine release and ventilation time after cardiac surgery. J Am Coll Cardiol 2001, 38:124-130.
31. Moretti E.W., Newman M.F., Muhlbaier L.H., Whellan D., Petersen R.P., Rossignol D., McCants C.B., Phillips-Bute B., nett-Guerrero E. Effects of decreased preoperative endotoxin core antibody levels on long-term mortality after coronary artery bypass graft surgery. Arch Surg 2006, 141:637-641.
32. Down J.F., Barclay G.R., nett-Guerrero E., Hamilton-Davies C., Stephens R., Grocott M.P., Mythen M.G. A descriptive study of the variation in baseline levels of antiendotoxin core antibodies between US and UK populations. J Endotoxin Res 2004, 10:195-196.
33. Teoh K.H., Bradley C.A., Gauldie J., Burrows H. Steroid inhibition of cytokine-mediated vasodilation after warm heart surgery. Circulation 1995, 92:II347-II353.
34. Kawamura T., Inada K., Okada H., Okada K., Wakusawa R. Methylprednisolone inhibits increase of interleukin 8 and 6 during open heart surgery. Can J Anaesth 1995, 42:399-403.
35. Bourbon A., Vionnet M., Leprince P., Vaissier E., Copeland J., McDonagh P., Debre P., Gandjbakhch I. The effect of methylprednisolone treatment on the cardiopulmonary bypass-induced systemic inflammatory response. Eur J Cardiothorac Surg 2004, 26:932-938.
36. Chaney M.A., Nikolov M.P., Blakeman B., Bakhos M., Slogoff S. Pulmonary effects of methylprednisolone in patients undergoing coronary artery bypass grafting and early tracheal extubation. Anesth Analg 1998, 87:27-33.
37. Karlstad M.D., Patteson S.K., Guszcza J.A., Langdon R., Chesney J.T. Methylprednisolone does not influence endotoxin translocation during cardiopulmonary bypass. J Cardiothorac Vasc Anesth 1993, 7:23-27.
38. Wan S., LeClerc J.L., Huynh C.H., Schmartz D., DeSmet J.M., Yim A.P., Vincent J.L. Does steroid pretreatment increase endotoxin release during clinical cardiopulmonary bypass?. J Thorac Cardiovasc Surg 1999, 117:1004-1008.
39. Oudemans-van Straaten H.M., Jansen P.G., Velthuis H., Stoutenbeek C.P., Zandstra D.F., Deventer S.J., Sturk A., Wildevuur C.R., Eijsman L. Endotoxaemia and postoperative hypermetabolism in coronary artery bypass surgery: the role of ketanserin. Br J Anaesth 1996, 77:473-479.
40. Sturman J.A. Taurine in development. Physiol Rev 1993, 73:119-147.
41. Doddakula K.K., Neary P.M., Wang J.H., Sookhai S., O'Donnell A., Aherne T., Bouchier-Hayes D.J., Redmond H.P. The antiendotoxin agent taurolidine potentially reduces ischemia/reperfusion injury through its metabolite taurine. Surgery 2010, doi:10.10.16/j.surg.2010.01.006.
42. de Smet A.M., Kluytmans J.A., Cooper B.S., Mascini E.M., Benus R.F., van der Werf T.S., van der Hoeven J.G., Pickkers P., Bogaers-Hofman D., van der Meer N.J., Bernards A.T., Kuijper E.J., Joore J.C., Leverstein-van Hall M.A., Bindels A.J., Jansz A.R., Wesselink R.M., de Jongh B.M., Dennesen P.J., van Asselt G.J., te Velde L.F., Frenay I.H., Kaasjager K., Bosch F.H., van I.M., Thijsen S.F., Kluge G.H., Pauw W., de Vries J.W., Kaan J.A., Arends J.P., Aarts L.P., Sturm P.D., Harinck H.I., Voss A., Uijtendaal E.V., Blok H.E., Thieme Groen E.S., Pouw M.E., Kalkman C.J., Bonten M.J. Decontamination of the digestive tract and oropharynx in ICU patients. N Engl J Med 2009, 360:20-31.
43. Martinez-Pellus A.E., Merino P., Bru M., Conejero R., Seller G., Munoz C., Fuentes T., Gonzalez G., Alvarez B. Can selective digestive decontamination avoid the endotoxemia and cytokine activation promoted by cardiopulmonary bypass?. Crit Care Med 1993, 21:1684-1691.
44. Bouter H., Schippers E.F., Luelmo S.A., Versteegh M.I., Ros P., Guiot H.F., Frolich M., van Dissel J.T. No effect of preoperative selective gut decontamination on endotoxemia and cytokine activation during cardiopulmonary bypass: a randomized, placebo-controlled study. Crit Care Med 2002, 30:38-43.
45. Taggart D.P., Sundaram S., McCartney C., Bowman A., McIntyre H., Courtney J.M., Wheatley D.J. Endotoxemia, complement, and white blood cell activation in cardiac surgery: a randomized trial of laxatives and pulsatile perfusion. Ann Thorac Surg 1994, 57:376-382.
46. Mullarkey M., Rose J.R., Bristol J., Kawata T., Kimura A., Kobayashi S., Przetak M., Chow J., Gusovsky F., Christ W.J., Rossignol D.P. Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist. J Pharmacol Exp Ther 2003, 304:1093-1102.
47. Bennett-Guerrero E., Grocott H.P., Levy J.H., Stierer K.A., Hogue C.W., Cheung A.T., Newman M.F., Carter A.A., Rossignol D.P., Collard C.D. A phase II, double-blind, placebo-controlled, ascending-dose study of Eritoran (E5564), a lipid A antagonist, in patients undergoing cardiac surgery with cardiopulmonary bypass. Anesth Analg 2007, 104:378-383.
48. Poelstra K., Bakker W.W., Klok P.A., Hardonk M.J., Meijer D.K. A physiologic function for alkaline phosphatase: endotoxin detoxification. Lab Invest 1997, 76:319-327.
49. Bentala H., Verweij W.R., Huizinga-van der Vlag A., van Loenen-Weemaes A.M., Meijer D.K., Poelstra K. Removal of phosphate from lipid A as a strategy to detoxify lipopolysaccharide. Shock 2002, 18:561-566.
50. Bates J.M., Akerlund J., Mittge E., Guillemin K. Intestinal alkaline phosphatase detoxifies lipopolysaccharide and prevents inflammation in zebrafish in response to the gut microbiota. Cell Host Microbe 2007, 2:371-382.
51. Beumer C., Wulferink M., Raaben W., Fiechter D., Brands R., Seinen W. Calf intestinal alkaline phosphatase, a novel therapeutic drug for lipopolysaccharide (LPS)-mediated diseases, attenuates LPS toxicity in mice and piglets. J Pharmacol Exp Ther 2003, 307:737-744.
52. Kats S., Brands R., Seinen W., de J.W., Bekker M.W., Hamad M.A., Tan M.E., Schonberger J.P. Anti-inflammatory effects of alkaline phosphatase in coronary artery bypass surgery with cardiopulmonary bypass. Recent Pat Inflamm Allergy Drug Discov 2009, 3:214-220.
53. Blomquist S., Gustafsson V., Manolopoulos T., Pierre L. Clinical experience with a novel endotoxin adsorbtion device in patients undergoing cardiac surgery. Perfusion 2009, 24:13-17.
54. De Silva R.J., Armstrong J., Bottrill F., Goldsmith K., Colah S., Vuylsteke A. A lipopolysaccharide adsorber in adult cardiopulmonary bypass: a single centre randomized controlled pilot trial. Interact Cardiovasc Thorac Surg 2010, 11(1):86-92.
55. Tsuzuki H., Tani T., Ueyama H., Kodama M. Lipopolysaccharide: neutralization by polymyxin B shuts down the signaling pathway of nuclear factor kappaB in peripheral blood mononuclear cells, even during activation. J Surg Res 2001, 100:127-134.
56. Vincent J.L., Laterre P.F., Cohen J., Burchardi H., Bruining H., Lerma F.A., Wittebole X., De B.D., Brett S., Marzo D., Nakamura H., John S. A pilot-controlled study of a polymyxin B-immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intra-abdominal infection. Shock 2005, 23:400-405.
57. Ohki S., Oshima K., Takeyoshi I., Matsumoto K., Morishita Y. Endotoxin removal with a polymyxin B-immobilized hemoperfusion cartridge improves cardiopulmonary function after cardiopulmonary bypass. J Surg Res 2008, 145:74-79.
58. Raja S.G., Berg G.A. Impact of off-pump coronary artery bypass surgery on systemic inflammation: current best available evidence. J Card Surg 2007, 22:445-455.
59. Aydin N.B., Gercekoglu H., Aksu B., Ozkul V., Sener T., Kiygil I., Turkoglu T., Cimen S., Babacan F., Demirtas M. Endotoxemia in coronary artery bypass surgery: a comparison of the off-pump technique and conventional cardiopulmonary bypass. J Thorac Cardiovasc Surg 2003, 125:843-848.
60. Watarida S., Mori A., Onoe M., Tabata R., Shiraishi S., Sugita T., Nojima T., Nakajima Y., Matsuno S. A clinical study on the effects of pulsatile cardiopulmonary bypass on the blood endotoxin levels. J Thorac Cardiovasc Surg 1994, 108:620-625.
61. Neuhof C., Wendling J., Dapper F., Bauer J., Zickmann B., Jochum M., Tillmanns H., Neuhoft H. Endotoxemia and cytokine generation in cardiac surgery in relation to flow mode and duration of cardiopulmonary bypass. Shock 2001, 16(Suppl. 1):39-43.
62. Rasmussen B.S., Sollid J., Knudsen L., Christensen T., Toft E., Tonnesen E. The release of systemic inflammatory mediators is independent of cardiopulmonary bypass temperature. J Cardiothorac Vasc Anesth 2007, 21:191-196.
63. Gercekoglu H., Tarim O., Agar I., Korukcu A., Karabulut H., Soydemir H., Sokullu O., Toklu H., Johansson C.B., Yigiter B., Kopman E. Effects of hypothermia on blood endogenous endotoxin levels during cardiopulmonary bypass. J Card Surg 1997, 12:223-227.